Literature DB >> 16357447

Clinical significance of anti-CCP antibodies in rheumatoid arthritis.

Tsuneyo Mimori1.   

Abstract

A number of novel autoantibodies have been recently described in rheumatoid arthritis (RA), and their clinical significance and possible pathogenic roles have been discussed. In particular, new autoantibodies to citrullinated proteins such as filaggrin and its circular form (cyclic citrullinated peptide: CCP) are especially noteworthy because of their high sensitivity and high specificity. There are many studies that anti-CCP antibodies may serve as a powerful serologic marker for early diagnosis of RA and prognostic prediction of joint destruction. Anti-citrullinated protein antibodies are locally produced in RA joints, and citrullinated proteins (most are fibrins) are localized in RA synovial tissue. This finding strongly suggests a possibility that local citrullination of intraarticular proteins might be the initial event leading to autoantibody production in RA. Genetic factors such as a gene polymorphism of the citrullinating enzyme, PADI, might be associated with the breakage of self-tolerance and induction of autoimmunity against citrullinated proteins.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16357447     DOI: 10.2169/internalmedicine.44.1122

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  13 in total

1.  Anti-cyclic citrullinated peptide and rheumatoid factor in HIV positive patients.

Authors:  Zeljko Romic; Lovorka Derek; Vitomir Burek; Adriana Unic; Tihana Serdar; Domagoj Marijancevic; Jadranka Morovic-Vergles; Josko Mitrovic; Mladen Petrovecki
Journal:  Rheumatol Int       Date:  2010-05-27       Impact factor: 2.631

2.  Rheumatoid factor and antibodies against citrullinated peptides in Moroccan patients with rheumatoid arthritis: association with disease parameters and quality of life.

Authors:  Yousra Ibn Yacoub; Bouchra Amine; Assia Laatiris; Najia Hajjaj-Hassouni
Journal:  Clin Rheumatol       Date:  2011-08-04       Impact factor: 2.980

3.  Discriminative and diagnostic value of anti-cyclic citrullinated peptide antibodies in Iranian patients with rheumatoid arthritis.

Authors:  Jamileh Moghimi; Raheb Ghorbani; Farnaz Hasani; Mehrdad Sheikhvatan
Journal:  Rheumatol Int       Date:  2012-04-03       Impact factor: 2.631

Review 4.  Diagnostic value of anti-cyclic citrullinated peptide antibody for rheumatoid arthritis in a Chinese population: a meta-analysis.

Authors:  Fei Gao; Lei Ren; Cai-Qin Zhang; Feng-Yun Mu; Yan-Qiu You; Yan-Hong Liu
Journal:  Rheumatol Int       Date:  2011-09-30       Impact factor: 2.631

5.  Anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis.

Authors:  R Gupta; M M Thabah; B Vaidya; S Gupta; R Lodha; S K Kabra
Journal:  Indian J Pediatr       Date:  2010-02-05       Impact factor: 1.967

6.  Enhanced MRI in early undifferentiated oligoarthritis of the knee joints: improvements already visible after 2 months of DMARDs treatment.

Authors:  Yasser Emad; Yasser Ragab; Ahmed Shaarawy; Hala Raafat; H A El-Kiki; Johannes J Rasker
Journal:  Clin Rheumatol       Date:  2008-06-18       Impact factor: 2.980

7.  Significance of anti-CCP antibodies in modification of 1987 ACR classification criteria in diagnosis of rheumatoid arthritis.

Authors:  Jinxia Zhao; Xiangyuan Liu; Zhimin Wang; Zhanguo Li
Journal:  Clin Rheumatol       Date:  2009-10-15       Impact factor: 2.980

8.  Multicentric reticulohistiocytosis with positive anticyclic citrullinated antibodies.

Authors:  Anupama Chauhan; Zhanna Mikulik; Kevin V Hackshaw
Journal:  J Natl Med Assoc       Date:  2007-06       Impact factor: 1.798

9.  Diagnostic value of anti-cyclic citrullinated peptide antibodies in northern Chinese Han patients with rheumatoid arthritis and its correlation with disease activity.

Authors:  Hui Li; Wuqi Song; Yang Li; Yanhong Liu; Jing Bai; Xiu Li; Fengyun Mu; Yao Wang; Fengshan Zhang; Liju Su; Fengmin Zhang
Journal:  Clin Rheumatol       Date:  2010-01-05       Impact factor: 2.980

10.  Targeted therapies in rheumatoid arthritis: Focus on rituximab.

Authors:  Y K Teng; T W Huizinga; J M van Laar
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.